Home › Rexahn Awarded Patent In Europe For Cancer Drug Archexin
 

Keywords :   


Rexahn Awarded Patent In Europe For Cancer Drug Archexin

2013-10-02 07:43:36| drugdiscoveryonline News Articles

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, recently announced that the European Patent Office has granted the Company a patent, EP 1546180, for its clinical development candidate Archexin and its use for inhibiting the activated form of Akt-1 (phospho-Akt1)for the treatment of cancer

Tags: europe drug cancer patent

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
05.10Hurricane Leslie Graphics
05.10Hurricane Leslie Forecast Discussion Number 11
05.10Hurricane Leslie Wind Speed Probabilities Number 11
05.10Hurricane Leslie Public Advisory Number 11
05.10Summary for Hurricane Leslie (AT3/AL132024)
05.10Hurricane Leslie Forecast Advisory Number 11
05.10Hurricane Kirk Graphics
05.10Hurricane Kirk Forecast Discussion Number 23
More »